Engineered immune cells battle advanced blood cancers in new trial
NCT ID NCT03642626
Summary
This study is testing several FDA-approved CAR-T cell therapies for patients whose blood cancers have returned or not responded to standard treatments. It involves about 150 participants with conditions like acute lymphoblastic leukemia and various lymphomas. The main goals are to see how well the cancers respond to the treatment and to monitor serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.